Garadacimab for preventing attacks of hereditary angioedema

Garadacimab is in clinical development for preventing attacks in people with hereditary angioedema (HAE). HAE is a rare and potentially life-threating type of angioedema, a condition that causes sudden swelling. There are two types of HAE. Type I is more common and occurs because the body has abnormally low levels of proteins that help regulate bodily functions, such as fluids moving in and out of cells. Type II is less common and is caused by the body producing abnormal proteins. People who have HAE have a 50% chance of passing it on to their children. Symptoms of angioedema include swollen skin, mainly around the hands, feet, eyes, lips, and genitals. In people with HAE, symptoms can keep recurring and become more severe. They can experience swelling of the throat or voice-box, which leads to pain, difficulties in swallowing and speaking, and can lead to potentially life-threatening oxygen deprivation.